Drug Trial Radar · NCT03517176
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 31, 2018
Primary completion
Jun 19, 2020
Study completion Jun 19, 2020
Sponsor
- Lead sponsor
- Lisata Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
Conditions
- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
Interventions
CEND-1Drug
CEND-1 will be provided as concentrate for solution to be administered via IV injection.
Nab-paclitaxelDrug
Nab-paclitaxel will be provided as solution to be administered via IV infusion.
GemcitabineDrug
Gemcitabine will be provided as solution to be administered via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safe doses of CEND-1 when given alone or in combination with nabpaclitaxel and gemcitabineTime frame: Escalation Phase: From Day 1 of the run-in until Day 28 of Cycle 1 (cycle length=28 days)
- Optimal Biological Dose (OBD) of CEND-1 when given in combinationTime frame: Expansion Phase: from baseline until treatment discontinuation and approximately 30 days after last dose (cycle length=28 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Alfred Hospital
Melbourne, Victoria, Australia
St John of God Hospital
Subiaco, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.